Advertisement
Advertisement
CLDX
Celldex Therapeutics, Inc
32.55
USDSponsored
+0.87
+2.73%
Mar 26, 11:46 UTC -4
Open
CLDX Earnings Reports
Positive Surprise Ratio
CLDX beat 28 of 40 last estimates.
70%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$991.66K
/-$1.16
Implied change from Q4 25 (Revenue/ EPS)
+719.56%
/-4.92%
Implied change from Q1 25 (Revenue/ EPS)
+42.69%
/+43.21%
Celldex Therapeutics, Inc earnings per share and revenue
On Feb 25, 2026, CLDX reported earnings of -1.22 USD per share (EPS) for Q4 25, missing the estimate of -1.02 USD, resulting in a -18.58% surprise. Revenue reached 121.00 thousand, compared to an expected 1.51 million, with a -91.97% difference. The market reacted with a -0.58% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -1.16 USD, with revenue projected to reach 991.66 thousand USD, implying an decrease of -4.92% EPS, and increase of 719.56% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Celldex Therapeutics, Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Celldex Therapeutics, Inc reported EPS of -$1.22, missing estimates by -18.58%, and revenue of $121.00K, -91.97% below expectations.
How did the market react to Celldex Therapeutics, Inc's Q4 2025 earnings?
The stock price moved down -0.58%, changed from $30.82 before the earnings release to $30.64 the day after.
When is Celldex Therapeutics, Inc expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Celldex Therapeutics, Inc's next earnings report?
Based on 10
analysts, Celldex Therapeutics, Inc is expected to report EPS of -$1.16 and revenue of $991.66K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement